The latest Phase 2b trial activations follow the first dosings at US clinical sites in December 2017.
Opthea Ltd (ASX:OPT) has dosed the first patients in Europe and Israel in its Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD).
This follows the first dosings of OPT-302, a novel VEGF-C/D ‘Trap’ therapy in combination with ranibizumab (Lucentis®), at clinical sites across the US in December 2017.
Opthea, a developer of novel biologic therapies for the treatment of eye diseases, is staging the Phase 2b trial internationally.
Patients from more than 50 clinical sites in the US are being enrolled and the company is on track to open six trial sites in Israel and more than 50 across eight European countries.
These comprise the UK, France, Poland, Hungary, Spain, Latvia, Italy and the Czech Republic.
All countries and sites have been selected based on experience with conducting ophthalmic clinical trials with anti-VEGF-A therapies.
Read the article by John Miller at ProActiveInvestors Australia.